Helus Pharma has appointed Dr. Freda Lewis-Hall to its board of directors, where she will also serve as chair of the company's Scientific Advisory Committee, subject to approval by Cboe Canada. Dr. Lewis-Hall brings more than 40 years of experience across clinical care, research, academia and senior biopharmaceutical leadership, including more than a decade on Pfizer's executive leadership team as executive vice president and chief medical officer. She has also held leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation and Eli Lilly and Company.
A Distinguished Fellow of the American Psychiatric Association and former advisor to the National Institute of Mental Health, Dr. Lewis-Hall will provide scientific, clinical and regulatory governance across Helus' portfolio as the company advances its novel serotonergic agonist programs targeting serious mental health conditions. This appointment comes at a critical time for Helus Pharma, which is developing proprietary NSAs - novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity.
The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 development for generalized anxiety disorder, and the company maintains an extensive research portfolio of investigational NSAs.
For business and technology leaders monitoring the intersection of healthcare innovation and investment opportunities, this appointment signals Helus Pharma's commitment to rigorous scientific oversight and regulatory strategy. Dr. Lewis-Hall's extensive experience at major pharmaceutical companies, particularly her decade-long tenure at Pfizer where she served as executive vice president and chief medical officer, brings valuable perspective on drug development, clinical trial design, and regulatory pathways. Her background in psychiatric medicine and previous advisory role with the National Institute of Mental Health provides specialized expertise relevant to Helus' focus on mental health therapeutics.
The timing of this leadership addition coincides with Helus Pharma's advancement of its clinical programs. HLP003's Breakthrough Therapy Designation from the FDA indicates the agency's recognition of the drug's potential to address unmet medical needs in major depressive disorder. This regulatory designation can expedite the development and review process for drugs intended to treat serious conditions when preliminary clinical evidence demonstrates substantial improvement over available therapies. For investors and industry observers, the combination of experienced leadership and promising clinical assets suggests Helus Pharma is positioning itself strategically in the competitive mental health therapeutics market.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. The company updates and additional information are available at https://www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
